General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
(SAVA) Technical Data | news.google.com • |
Cassava Sciences stock gets price target boost By Investing.com | news.google.com • |
Cassava Sciences stock gets price target boost By Investing.com | news.google.com • |
Peering Into Cassava Sciences's Recent Short Interest- Benzinga | news.google.com • |
Cassava Sciences (NASDAQ:SAVA) Shares Down 6% | news.google.com • |
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam | globenewswire.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-10 | 2024-03 | -0.51 | -1.41 | -0.9 | -176.47% |
2024-02-28 | 2023-12 | -0.4 | -0.5 | -0.1 | -25.00% |
2023-11-07 | 2023-09 | -0.9 | -0.61 | 0.29 | 32.22% |
2023-08-03 | 2023-06 | -0.58 | -0.63 | -0.05 | -8.62% |
2023-05-01 | 2023-03 | -0.56 | -0.58 | -0.02 | -3.57% |
2023-02-28 | 2022-12 | -0.58 | -0.47 | 0.11 | 18.97% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-07 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-07-05 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-10 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-05-08 | HC Wainwright & Co. | Upgrade | Buy | |
2023-03-05 | HC Wainwright & Co. | Upgrade | Buy | |
2023-01-23 | HC Wainwright & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2018-10-02 | ARMISTICE CAPITAL L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
2023-05-23 | BARBIER REMI | Chief Executive Officer | 0.00 | Conversion of Exercise of derivative security |
2024-04-22 | BARRY RICHARD J | Director | 0.00 | Conversion of Exercise of derivative security |
2022-10-02 | FRIEDMANN NADAV | Officer and Director | 80.05K | Conversion of Exercise of derivative security |
2023-04-30 | GUSSIN ROBERT Z | Director | 10.62K | Conversion of Exercise of derivative security |
2024-04-17 | KUPIEC JAMES WILLIAM | Officer | 4.00K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 2.75M | 67.35M | 6.54% |
2023-06-29 | Vanguard Group Inc | 2.25M | 55.16M | 5.36% |
2023-06-29 | State Street Corporation | 952.09K | 23.35M | 2.27% |
2023-06-29 | Geode Capital Management, LLC | 803.31K | 19.70M | 1.91% |
2023-06-29 | Gallacher Capital Management LLC | 583.29K | 14.30M | 1.39% |
2023-06-29 | Northern Trust Corporation | 370.64K | 9.09M | 0.88% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.23M | 30.21M | 2.94% |
2023-08-30 | iShares Russell 2000 ETF | 908.42K | 19.05M | 2.16% |
2023-06-29 | Vanguard Extended Market Index Fund | 542.35K | 13.30M | 1.29% |
2023-07-30 | Fidelity Small Cap Index Fund | 353.09K | 7.76M | 0.84% |
2023-08-30 | iShares Russell 2000 Growth ETF | 333.17K | 6.99M | 0.79% |
2023-05-30 | Fidelity Extended Market Index Fund | 202.34K | 4.60M | 0.48% |
Dividend | Date |
---|---|
0.75 | 2012-12-13 |
2 | 2010-12-13 |
Split | Date |
---|---|
1 : 7 | 2017-05-10 |
Would love to see Dr. Bredt, Adrian H, Elizabeth Bik, and Orie Shafer’s face about now…
Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi
-- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.
Shorts ran out of shares to by, relying on puts for now…
Latest report is a big nothing burger. Another wave of short and distort. A gift for those the read the data updates. Price is a double discount.
For you longs that want to stay informed, follow Matt Nachtrab on Twitter.
Retailers! Stock was a gift at $16.45, great opportunity to pick up discount shares with the added benefit of driving nails into a unethical short campaign. Go!
Gosh, another serious gift by the shorts. Unloaded the dry powder at a steal…
Another anonymous individual with short positions… imagine that.
Cheap shares! Get ya cheap shares here!!
I’m thinking true longs like myself are loaded up relative to personal risk/value assessments, we aren’t selling, we aren’t planning to sell even when this flys because $SAVA is a ground breaking drug. We are getting very near 52 week lows, and could go back to $13 or so - all good, Shorts are giving us a gift to get ridiculously low bargain shares with little to lose and even more to gain. All I can say is thank you shorts, seriously big thanks.
Thing is, most of us longs are loaded up relative to our personal risk/value assessments and we aren’t selling, planning to sell, are averaged down and in good shape… So if shorts want to
2 years after Dr. Bredt and Jordan Thomas' Citizen Petition against $SAVA's Phase 3 Alzheimer's drug, Simufilam, the fog starts to lift and I'm more bullish than ever. Here's why:
Large phase 3 trials, despite odds, are near full enrollment. Amid false claims, media smearing, and a storm brewed by unethical short sellers, the #FDA didn't halt the trials. Families trust the evidence of the drug's safety & efficacy.
Solid evidence continues to support Simufilam in slowing AD. Continuous positive data corroborates that MMSE 21+ AD patients see cognition improvement even 18 months into treatment, reinforcing the drug's safety.
The company fought back. They hired Chris Cook, sued the baseless short sellers, and bravely sued for defamation. The SEC and DOJ investigations were addressed, paving the way for their civil offense and defense.
Breakthrough research continues. Hoau Wang's published work on the mTOR pathway, despite adversities, reflect his unwavering commitment to dementia research. They cancelled him so he got to work meticulously dissecting the mTOR pathway to prove Simufilam is impacting the disease there as well. frontiersin.org/articles/10.33…
Research FUD was tackled head-on. Lindsay Burns' published work emphasized the validity of their research against baseless criticisms. pubmed.ncbi.nlm.nih.gov/37291958/
They expanded their team with industry pros. In the face of smear campaigns, $SAVA broadened their team with industry veterans. See linked in... tinyurl.com/36msue4t
Families continue to support the trials. The treatment beneficiaries remain vocal about their support and confusion over the shorts' attack on $SAVA.
Short Seller attacks will soon be proven as a hoax. No concrete evidence of fraud was found. Yes, mistakes were made - science is complex, and they are a small team that stood strong against global backlash.
I am proud to support $SAVA and urge others to do the same. They are serving Alzheimer's patients, and could use more support. Let's stand together against unethical short attacks for the sake of future Alzheimer's victims. #AlzheimersResearch #StandWithSAVA @alzassociation @TheADDF @UsAgainstAlz @alzheimerssoc Feel free to message me with questions.
Big and very intentional covers going on. Can’t wait for short money to trickle down.
Considering how difficult is is to beat the market with individual stock trading, and as successful as the shorts have been thus far, perhaps its time they hang on the gallos they built. This price is a gift considering the data and potential. We are in a home stretch gather what you can afford, and hold it tight…
Great Read by Matt Nachtrab.
Shorts are gifting us longs with deliciously cheap shares…
https://x.com/mattnachtrab/status/1695023060317798813?s=46&t=U8sCionwrY2s_Kqs8IR5XA
Bought a bunch @ $16.80 yesterday, but still anticipating better deals will come until solid news is made public. That said, we are in the hour glass, dont sell. Hold and eat ramen if you have to, that ramen will turn to Angus beef soon enough.
$SAVA amazing folks are selling at this price - takes some confidence and quiet to be still and hold as the price goes back to $13ish. Get your powder barrels ready to sweep up in the dip.
Meanwhile $ALXO $BLUE $TNYA are all in bargain territory…
$SAVA Patience Longs, let the last strategy to invest profitably be ours. Rug pulls will be ending in the weeks to come. $13ish is the next stronghold. Let them run it down and then pounce with a substantial investment to average the losses to a phenomenal win!!